18F-FDG PET/CT is a powerful tool in Pulmonology, primarily for lung cancer, particularly primary and secondary lung tumors, and pleural tumors, providing both anatomical and metabolic data for diagnosis, staging, and disease monitoring. It helps differentiate malignant from benign pulmonary nodules, accurately assesses the extent of cancer (TNM staging), detects metastases, and guides radiotherapy planning. Beyond cancer, it can also be used to evaluate lung inflammation in conditions such as asthma, cystic fibrosis, and Acute Respiratory Distress Syndrome (ARDS), as well as in granulomatous lung diseases.
Key Applications in Lung Cancer Management
Key Applications in Mesothelioma Management
Applications in Non-Oncological Pulmonary Diseases
18F-FDG is the most widely used clinical radiopharmaceutical. While it is a non-specific marker of inflammation, activated monocytes, macrophages, and neutrophils in inflammation and infection exhibit increased 18F-FDG uptake compared to normal cells.
Limitations
Non-specific Uptake: FDG uptake is not specific to infection or inflammation and can also be elevated in malignancies. Therefore, findings must be interpreted alongside the patient's medical history and other diagnostic information.
Not a First-Line Tool: FDG PET/CT is generally considered a complementary method to conventional imaging and is not typically the first-line imaging modality for these conditions.
Key Applications in Lung Cancer Management
- Pulmonary Nodule Characterization: PET/CT helps determine whether a pulmonary nodule observed on CT is malignant by detecting increased glucose metabolism, although some benign conditions, such as infections, also exhibit increased metabolic activity.
- Staging and Restaging: It is a critical examination for determining the stage of lung cancer (TNM staging) and evaluating metastasis to lymph nodes and distant organs, which guides treatment decisions.
- Monitoring Treatment Response: After treatment, PET/CT can assess treatment efficacy by monitoring metabolic changes in the tumor.
- Radiotherapy Planning: The ability to determine the extent of active disease makes it invaluable for planning radiotherapy treatments.
Key Applications in Mesothelioma Management
- Biopsy Guidance: PET/CT can identify the most metabolically active areas of the tumor, allowing selection of the optimal site for biopsy, which can improve diagnostic accuracy.
- Exclusion of Extrathoracic Disease: In confirmed mesothelioma, for patients who are candidates for radical surgical treatment.
Applications in Non-Oncological Pulmonary Diseases
18F-FDG is the most widely used clinical radiopharmaceutical. While it is a non-specific marker of inflammation, activated monocytes, macrophages, and neutrophils in inflammation and infection exhibit increased 18F-FDG uptake compared to normal cells.
- Inflammatory Processes: 18F-FDG PET/CT can identify areas of inflammation in the lungs, helping to evaluate inflammatory cell activity in conditions such as:
- Asthma: As a non-invasive method for evaluating airway inflammation and the effects of anti-inflammatory therapies.
- Cystic Fibrosis: To identify patients with significant inflammation and faster deterioration of pulmonary function.
- Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS): FDG PET/CT can monitor the level and activity of disease over time and can be used to evaluate the efficacy of anti-inflammatory therapies.
- Complementary to Other Methods: It offers a comprehensive picture of lung inflammation, complementing less invasive methods such as bronchoalveolar lavage or more invasive open lung biopsies.
- Granulomatous Diseases (Sarcoidosis, Tuberculosis): For diagnosis and monitoring of treatment response in patients with histologically confirmed sarcoidosis, and for delineating disease extent and evaluating occult extrapulmonary lesions in tuberculosis.
- Fungal Infections: FDG PET/CT is used for the diagnosis and monitoring of various fungal infections, including aspergillosis, candidiasis, and histoplasmosis.
Limitations
Non-specific Uptake: FDG uptake is not specific to infection or inflammation and can also be elevated in malignancies. Therefore, findings must be interpreted alongside the patient's medical history and other diagnostic information.
Not a First-Line Tool: FDG PET/CT is generally considered a complementary method to conventional imaging and is not typically the first-line imaging modality for these conditions.